Safety of one influenza vaccine in children should not be extrapolated to assumed safety of all influenza vaccines in children. All vaccines intended for use in children require safety testing in the target age group, especially in young children. Live attenuated vaccines have not been studied adequately in children under 2 years of age to determine the risks of adverse events more studies are needed to address this and several other priority safety issues with all influenza vaccines in children. There can be differences in the safety of vaccines in different populations due to underlying differences in genetic predisposition to the adverse event. Some adverse events, such as fever and febrile seizures, are more common in children than adults. Most influenza vaccines are generally safe, but influenza vaccines can cause rare serious adverse events. Halsey, Neal A Talaat, Kawsar R Greenbaum, Adena Mensah, Eric Dudley, Matthew Z Proveaux, Tina Salmon, Daniel A The safety of influenza vaccines in children: An Institute for Vaccine Safety white paper. In this commentary, we describe the current state of knowledge with respect to the safety of quadrivalent meningococcal conjugate vaccines, and we identify potential areas for safety research for these vaccines. More recently, a study found an elevated risk of Bell's palsy when Menveo was administered concomitantly with other vaccines but no association was found when the vaccine was administered alone. Although early reports raised concerns about a possible association of Menactra with Guillain-Barré syndrome, a comprehensive safety review determined that if such risk existed it was no more than 0.66 cases per 1 million vaccinations. Two such vaccines are currently licensed and available in the United States, Menactra® (Sanofi Pasteur) and Menveo® (GlaxoSmithKline), and usage in the adolescent population has steadily increased since their introduction. The main prevention strategy for invasive meningococcal disease in the United States is the routine vaccination of adolescents and other persons at increased risk of meningococcal disease with quadrivalent meningococcal conjugate vaccines. Invasive meningococcal disease, although rare, can present as sudden, life-threatening disease with high risk of mortality or severe long-term sequelae. PMID:15514229Ĭurrent safety issues with quadrivalent meningococcal conjugate vaccines. We highlight its recent recommendations on major issues, including the purported link between the measles–mumps–rubella vaccine and autism and the safety of the mumps, influenza, yellow fever, BCG, and smallpox vaccines as well as that of thiomersal-containing vaccines. We describe the principles on which the committee was established, its modus operandi, and the scope of the work undertaken, both present and future. The committee also assesses the implications of vaccine safety for practice worldwide and for WHO policies. Siegrist, Claire-Anne Wimalaratne, OmalaĮstablished in 1999, the Global Advisory Committee on Vaccine Safety advises the World Health Organization (WHO) on vaccine-related safety issues and enables WHO to respond promptly, efficiently, and with scientific rigor to issues of vaccine safety with potential global importance. Miller, Elizabeth Salisbury, David Schmitt, Heinz-J. Jacob Lambert, Paul-Henri MacDonald, Noni E. Bernatowska, Ewa Chen, Robert Clemens, John Dodoo, Alex N. A Global Perspective on Vaccine Safety and Public Health: The Global Advisory Committee on Vaccine Safetyįolb, Peter I.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |